FEED1 TRIAL

 A

5 KEY POINTS — EBNEO Commentary on the FEED1 Trial (Singh, 2026)

1. Early full enteral feeding improved care processes but not discharge timing
   Infants receiving full feeds from day 1 achieved enteral feeding faster, required less parenteral nutrition, fewer invasive lines, and less intensive care time — yet overall hospital stay did not shorten.

2. Hospital discharge is influenced by non-medical factors
   The unchanged length of stay suggests that discharge timing in moderate-to-late preterm infants is often determined by social, organisational, and administrative factors, rather than physiological readiness alone.

3. The trial challenges how neonatal “success” is defined
   FEED1 highlights that meaningful improvements in neonatal care may include:

   • reduced medicalisation

   • fewer central lines

   • lower infection exposure

   • less parenteral nutrition

   even if traditional endpoints like length of stay remain unchanged.

4. Intervention fidelity was a major limitation
   Only a minority of infants truly received exclusive enteral feeding from birth, and many deviated from protocol because of perceived feed intolerance, potentially underestimating the true benefits of the intervention.

5. FEED1 supports the safety of early feeding and reframes future research
   The study provides reassuring evidence that stable moderate-to-late preterm infants can safely receive full milk feeds from birth, while future work should focus on:

   • standardising feed intolerance criteria

   • identifying true barriers to discharge

   • evaluating higher-risk extremely preterm infants

   • assessing long-term neurodevelopmental outcomes.

NN RESUS

 A

3 TAKE-HOME POINTS — Delivery-Room PEEP Beyond 10 Minutes in ≥34-Week Infants (Davies et al., 2026)

1. Prolonged delivery-room PEEP/CPAP is uncommon but clinically important
   Most ≥34-week infants transition quickly after birth, so continuing PEEP beyond 10 minutes identifies a subgroup with more significant respiratory compromise and higher likelihood of escalation of care. (Resuscitation Council UK)

2. Persistent respiratory support often predicts NICU admission and further intervention
   Infants requiring prolonged PEEP are more likely to need ongoing respiratory support, NICU admission, investigation for underlying pathology (e.g. TTN, pneumonia, PPHN), and closer monitoring after initial stabilisation. Existing evidence suggests delivery-room CPAP/PEEP may reduce respiratory morbidity in selected infants but can also increase air-leak risk. (PMC)

3. There is limited evidence guiding prolonged DR-PEEP practice in term and late-preterm infants
   Current neonatal resuscitation guidance supports CPAP/PEEP for infants with respiratory distress, but evidence on optimal duration, thresholds for escalation, and outcomes beyond the delivery room remains sparse, highlighting the importance of standardised pathways and further research. (Resuscitation Council UK)

P RISK OF PN AFTER RSV

 A

5 TAKE-HOME POINTS — RSV Hospitalisation Age & Risk of Subsequent Bacterial Pneumonia (Videholm et al., 2026)

1. Large national cohort strengthens evidence
   The study followed ~1.6 million Swedish children and identified over 29,000 RSV hospitalisations, making this a robust population-level analysis of long-term respiratory outcomes.

2. RSV hospitalisation increases later pneumonia risk
   Children hospitalised for RSV had a significantly higher risk of subsequent bacterial pneumonia compared with those without RSV admission.

3. Older age at RSV hospitalisation = higher relative risk
   The risk of later bacterial pneumonia was greater when RSV hospitalisation occurred at older ages (especially 12–23 months) compared with infants under 6 months.

4. Risk is highest soon after RSV infection
   The association was strongest in the first 0–2 months after RSV hospitalisation, but elevated risk persisted beyond 3 months across all age groups.

5. Implications for prevention and risk stratification
   Findings suggest that preventing RSV—particularly beyond early infancy—and identifying higher-risk older infants may help reduce later bacterial pneumonia burden, though residual confounding (e.g., comorbidities) may partly influence results.

N OROMOTOR SKILLS X SPEECH DVPT

 A

3 KEY POINTS — Early Speech Milestones & Oral–Motor Development (Allison et al., 2026)

1. Better oral–motor skills are linked to earlier speech development
   Infants with higher scores on the Child Oral and Motor Proficiency Scale (ChOMPS) were more likely to have started babbling by 6 months, suggesting a relationship between motor control of the mouth and early speech emergence.

2. Stronger oral–motor development is associated with richer vocal output
   Higher ChOMPS scores were significantly associated with a larger variety of protophones (early speech-like sounds such as vowel- and consonant-like vocalisations) reported by parents.

3. Preterm birth and sex were not influential factors
   Neither prematurity nor infant sex affected babbling onset or phonetic inventory, indicating that oral–motor ability was a more important predictor than these demographic variables in this small sample.

N NN SVT

 A

5 KEY POINTS — Supraventricular Tachycardia in Newborns: 10-Year Multicentre Experience (Pasquinucci et al., 2026)

1. AV re-entrant tachycardia is the dominant mechanism
   Most neonatal SVT cases were due to atrioventricular re-entrant tachycardia (72%), with smaller proportions of AVNRT, PJRT, and focal atrial tachycardia.

2. Presentation is early and clinically significant
   Median onset occurred at ~14 days of life, and a notable proportion developed tachycardia-induced cardiomyopathy (28%), highlighting potential haemodynamic impact even in neonates.

3. Acute termination is usually achievable
   First-episode SVT was terminated by vagal manoeuvres (28%) or adenosine (47%), though some cases resolved spontaneously (13%), indicating generally good acute responsiveness.

4. Most infants require long-term therapy
   Nearly all patients (97%) needed maintenance antiarrhythmic treatment, typically for a prolonged period (median ~21 months), reflecting high recurrence risk.

5. Outcomes are generally good but management can be prolonged and complex
   Over ~3.75 years follow-up, recurrence after stopping therapy was uncommon, but some required electrophysiology studies and ablation, especially refractory cases. Biomarkers (e.g., NT-proBNP) and SVT subtype helped predict higher treatment burden.

A

This statement means that both blood test results and the specific electrical type of SVT can help identify which newborns are likely to have a more difficult or prolonged course of illness.

1. What is meant by “biomarkers (e.g., NT-proBNP)”?

• NT-proBNP (N-terminal pro–brain natriuretic peptide) is a hormone released by the heart when it is under strain or stress.

• In neonatal SVT, a high heart rate can reduce filling time and cardiac efficiency → the heart becomes “stretched” or stressed → NT-proBNP rises.

👉 So:

• Higher NT-proBNP = more cardiac stress

• This often correlates with:

  • poorer ventricular function

  • tachycardia-induced cardiomyopathy

  • need for more aggressive or prolonged treatment

---

2. What is meant by “SVT subtype”?

SVT is not one disease—it includes different electrical circuits:

• AV re-entrant tachycardia (AVRT) – most common, often accessory pathway (e.g., Wolff-Parkinson-White physiology)

• AV nodal re-entrant tachycardia (AVNRT) – less common in neonates

• Permanent junctional reciprocating tachycardia (PJRT) – often persistent and harder to control

• Focal atrial tachycardia – abnormal atrial focus firing

👉 Some types behave more aggressively than others:

• PJRT and focal atrial tachycardia tend to be:

  • more persistent

  • harder to terminate

  • more likely to recur

  • more likely to require multiple drugs or longer treatment

---

3. What does “predict higher treatment burden” mean in practice?

It means these factors are linked with:

• longer duration of antiarrhythmic therapy

• higher likelihood of combination therapy (more than one drug)

• increased need for ICU care or monitoring

• greater chance of recurrence after stopping treatment

• occasional need for electrophysiology study or ablation later in infancy

---

In simple terms

👉 If a newborn has:

• high NT-proBNP, and/or

• a more complex SVT type (like PJRT or focal atrial tachycardia),

they are more likely to have a tougher course requiring longer and more intensive treatment compared with simpler AVRT cases.

---

If you want, I can turn this into a one-line exam answer or viva response.

N Neonatal seizures NR TERM were associated with a high risk of mortality and about a quarter were later diagnosed with epilepsy and/or CP.

N BPD, PDA ADDS TO PRTERM NEURODVPT RISK